Inventor · disambiguated record
Goffredo Rosini
Also filed as: ROSINI GOFFREDO
16 granted patents·22 pending applications·384 citations·filing 1992–2022
95Inventor score
Top patents by PatentIndex Score
38 records- 0197US8158781B2Polymorphic forms α, β and γ of rifaximinVISCOMI GIUSEPPE CLAUDIO·Filed 2011·Granted Apr 17, 2012·27 cites·8 claims
- 0297US7902206B2Polymorphic forms α, β and γ of rifaximinALFA WASSERMANN SPA·Filed 2008·Granted Mar 8, 2011·28 cites·57 claims
- 0397US7045620B2Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparationsALFA WASSERMANN SPA·Filed 2003·Granted May 16, 2006·139 cites·20 claims
- 0496US8835452B2Polymorphic forms α, β and γ of rifaximinALFA WASSERMANN SPA·Filed 2012·Granted Sep 16, 2014·15 cites·21 claims
- 0596US7906542B2Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximinALFA WASSERMANN SPA·Filed 2008·Granted Mar 15, 2011·40 cites·25 claims
- 0695US8158644B2Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximinVISCOMI GIUSEPPE CLAUDIO·Filed 2011·Granted Apr 17, 2012·26 cites·20 claims
- 0795US7923553B2Processes for the production of polymorphic forms of rifaximinALFA WASSERMANN SPA·Filed 2008·Granted Apr 12, 2011·18 cites·46 claims
- 0895US7612199B2Polymorphic forms α, β, and γ of rifaximinALFA WASSERMANN SPA·Filed 2009·Granted Nov 3, 2009·45 cites·7 claims
- 0993US8853231B2Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximinALFA WASSERMANN SPA·Filed 2012·Granted Oct 7, 2014·15 cites·18 claims
- 1092US8173801B2Processes for the production of polymorphic forms of rifaximinVISCOMI GIUSEPPE CLAUDIO·Filed 2011·Granted May 8, 2012·14 cites·19 claims
- 1180US2022127283A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2022·Application pending·0 cites
- 1279US8318763B2Rifamycin derivativesVISCOMI GIUSEPPE CLAUDIO·Filed 2009·Granted Nov 27, 2012·5 cites·19 claims
- 1373US2020339599A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 1473US2019263829A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2019·Application pending·0 cites
- 1573US2020339600A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 1672US2015175627A1Polymorphic forms alpha, beta and gamma of rifaximinALFA WASSERMANN SPA·Filed 2014·Application pending·0 cites
- 1771US2019263830A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2019·Application pending·0 cites
- 1870US2019135831A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2018·Application pending·0 cites
- 1968US2019135830A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2018·Application pending·0 cites
- 2067US8765778B2Rifamycin derivativesALFA WASSERMANN SPA·Filed 2012·Granted Jul 1, 2014·1 cites·29 claims
- 2167US2018065987A1Polymorphic forms alpha, beta and gamma of rifaximinALFA WASSERMANN SPA·Filed 2017·Application pending·0 cites
- 2267US2008262024A1Rifaximin compositions and method of useVISCOMI GIUSEPPE CLAUDIO·Filed 2008·Application pending·0 cites
- 2367US2015182508A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFA WASSERMANN SPA·Filed 2014·Application pending·0 cites
- 2466US2012203000A1Polymorphic forms alpha, beta and gamma of rifaximinVISCOMI GIUSEPPE CLAUDIO·Filed 2012·Application pending·0 cites
- 2566US2017210758A1Polymorphic forms alpha, beta and gamma of rifaximinALFA WASSERMANN SPA·Filed 2016·Application pending·0 cites
- 2665US2018065988A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFA WASSERMANN SPA·Filed 2017·Application pending·0 cites
- 2763US2017210757A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFA WASSERMANN SPA·Filed 2016·Application pending·0 cites
- 2862US2012202989A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinVISCOMI GIUSEPPE CLAUDIO·Filed 2012·Application pending·0 cites
- 2958US2005272754A1Polymorphic forms of rifaximin, processes for their production and uses thereofALFA WASSERMANN SPA·Filed 2005·Application pending·0 cites
- 3057US2012258166A1Rifaximin compositions and method of useVISCOMI GIUSEPPE CLAUDIO·Filed 2012·Application pending·0 cites
- 3157US2022119410A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2021·Application pending·0 cites
- 3256US2012035202A1Rifaximin compositions and method of useVISCOMI GIUSEPPE CLAUDIO·Filed 2011·Application pending·0 cites
- 3354US2012214989A1Processes for the production of polymorphic forms of rifaximinVISCOMI GIUSEPPE CLAUDIO·Filed 2012·Application pending·0 cites
- 3454US2011086871A1Rifaximin compositions and method of useALFA WASSERMANN SPA·Filed 2010·Application pending·0 cites
- 3549US5191125AProcedure for the preparation of bicyclo [3.2.0]hept-2-en-7-onesENICHEM SPA·Filed 1992·Granted Mar 2, 1993·5 cites·5 claims
- 3646US5663389A3,4-Dihydro-2-iodomethyl-2,5,7,8-tetramethyl-2H-1-benzopyransALFA WASSERMANN SPA·Filed 1996·Granted Sep 2, 1997·3 cites·1 claims
- 3736US7019154B2Process for the production of 5-benzyl-3-furfuryl alcoholENDURA SPA·Filed 2002·Granted Mar 28, 2006·0 cites·35 claims
- 3833US5608084ALactones with antioxidising and hypolipidaemic activity useful in the therapy of the atherosclerosisALFA WASSERMANN SPA·Filed 1995·Granted Mar 4, 1997·3 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →